US-based pharma giant Eli Lilly has put its potential return to London on hold amid pricing and regulatory pressures in the capital, and could turn its sights to somewhere else in Europe. Speaking on a webinar today hosted by Hogan
Thank you for reading EG
Want to read more? Enjoy a story a week for FREE for one month.
Register
Find Out More